8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 15, 2005

MYLAN LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	1-9114	25-1211621
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1500 Corporate Drive
Canonsburg, PA 15317
(Address of principal executive offices)

(724) 514-1800
(Registrant’s telephone number, including area code)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

     o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

TABLE OF CONTENTS

	Item 8.01 – Other Events.
	Item 9.01 – Financial Statements and Exhibits.
SIGNATURE
EXHIBIT INDEX
Exhibit 99.1

Item 8.01 – Other Events.

     On July 15, 2005, Mylan Laboratories Inc. issued a press release announcing its pricing of $150 million aggregate principal amount of its
5-3/4% Senior Notes due 2010 and $350 million aggregate principal amount of its 6-3/8% Senior Notes due 2015. A copy of the press release is attached as Exhibit 99.1.

Item 9.01 – Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No.		Description
	99.1	Press release of Mylan Laboratories Inc., dated July 15, 2005.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MYLAN LABORATORIES INC.
Date: July 15, 2005	By:	/s/ Edward J. Borkowski
		Edward J. Borkowski
		Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
	99.1	Press release of Mylan Laboratories Inc., dated July 15, 2005.

EX-99.1

EXHIBIT 99.1

For Immediate Release	CONTACTS:	Patrick Fitzgerald (Media)
		Mylan Laboratories Inc.
		724.514.1800
		Kris King (Investor)
		Mylan Laboratories Inc.
		724.514.1800

Mylan Laboratories Announces Pricing of $500 Million Aggregate Principal Amount of Senior Notes

PITTSBURGH, PA—July 15, 2005—Mylan Laboratories Inc. (NYSE: MYL) announced today the pricing of $150 million aggregate principal amount of its Senior Notes due 2010 at 5-3/4% and $350 million aggregate principal amount of its Senior Notes due 2015 at 6-3/8%.

The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to persons outside the United States under Regulation S of the Securities Act. The transaction is expected to close on July 21, 2005.

Mylan intends to use the proceeds from the issue to fund a portion of its purchase of up to 48.8 million shares of its common stock (up to $1 billion) pursuant to its previously announced modified “Dutch auction” self-tender offer which was commenced on June 16, 2005. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on July 15, 2005, unless extended by Mylan.

The notes have not been registered under the Securities Act or securities laws of any state and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the Securities Act or the laws of any state. This press release shall not constitute an offer to sell or a solicitation of an offer to buy such notes in any jurisdiction in which such an offer or sale would be unlawful and is issued pursuant to Rule 135c under the Securities Act.

About Mylan

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

4

For more information about Mylan, visit www.mylan.com.

Forward-Looking Statements

This press release includes statements that constitute “forward-looking statements”, including with regard to the senior notes offering, such as the completion and timing thereof. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties regarding investor demand for the notes; prevailing market conditions; changes in economic and financial conditions of Mylan’s business; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan’s periodic filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.

Notwithstanding any statement in this press release to the contrary, the safe harbor protections of the Private Securities Litigation Reform Act of 1995 do not apply to statements made in connection with a tender offer.

###

5